List view / Grid view
10 March 2016 | By Victoria White
The ERADICATE Hp Phase III study was intended to evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed H. pylori bacterial infection...
The post-hoc analysis confirms the predictive nature of the relationship between baseline blood eosinophil counts and efficacy outcomes in patients treated with mepolizumab...
9 March 2016 | By GlobalData
The UK Department of Health’s rejection of a petition to expand the routine administration of MenB vaccine Bexsero may lead to parents and physicians to consider purchasing the vaccine themselves...
9 March 2016 | By Victoria White
From today, people in Israel with radioactive iodine refractory differentiated thyroid cancer will have access to Eisai’s Lenvima (lenvatinib)...
9 March 2016 | By Victoria White
Aprea says the funds will be used to advance the clinical development of its lead programme APR-246, a first-in-class anticancer compound reactivating the tumour suppressor protein p53...
9 March 2016 | By Victoria White
Cresemba (isavuconazonium sulfate) is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive aspergillosis and invasive mucormycosis...
8 March 2016 | By Victoria White
Sanat Chattopadhyay, who's appointment will be made effective on 1 April 2016, will succeed Willie A. Deese...
8 March 2016 | By Victoria White
The addition of Spiriva Respimat to other asthma maintenance therapies helps improve asthma symptom control regardless of allergy subtype...
8 March 2016 | By Victoria White
Upon concluding their joint venture, Sanofi Pasteur and MSD plan to integrate their respective European vaccine businesses into their operations...
8 March 2016 | By Systech International
Global brands focus on consumer safety at Amsterdam conference...
8 March 2016 | By Victoria White
The approval expands the use of Faslodex and offers additional options for US women with HR+, HER2- metastatic breast cancer…
8 March 2016 | By Victoria White
In UNCOVER-2, patients with plaque psoriasis who did not respond to etanercept achieved significant improvement in their psoriasis plaques when treated with ixekizumab...
8 March 2016 | By Victoria White
The FDA has accepted for review a new supplemental Biologics License (sBLA) for Merck’s Keytruda (pembrolizumab) to include data from KEYNOTE-010...
8 March 2016 | By Victoria White
New research looks at women's awareness of over-the-counter access to emergency contraceptives in Europe...
7 March 2016 | By Victoria White
BI 655066 is an anti-IL-23 monoclonal biologic antibody being evaluated in psoriasis, Crohn’s disease, psoriatic arthritis and asthma...
